- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.03. | Setting a new bar? Zealand Pharma touts 'placebo-like tolerability' for Roche-partnered weight loss drug | ||
| 05.03. | Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal | ||
| 05.03. | Senior FDA official refutes uniQure's claims amid controversy over Huntington's gene therapy | ||
| 05.03. | Alltrna undergoes third layoff round before entering clinic, cutting 35% of jobs | ||
| 05.03. | Pressure builds as back-and-forth between uniQure and FDA intensifies | ||
| 05.03. | Tenaya, Alnylam ink research collab to find gene targets for cardio drugs | ||
| 05.03. | PepGen hit with partial clinical hold, analysts blame 'understaffed FDA' | ||
| 04.03. | Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations | ||
| 04.03. | Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem' | ||
| 04.03. | Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option | ||
| 04.03. | UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidate | ||
| 04.03. | Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug | ||
| 03.03. | FDA details rationale for rejecting rare disease gene therapy from Regenxbio | ||
| 03.03. | Theravance halves headcount, ends all R&D work after phase 3 rare disease fail | ||
| 03.03. | New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program | ||
| 03.03. | Biohaven reduces scope of R&D cutbacks as pipeline progresses | ||
| 02.03. | Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline | ||
| 02.03. | TCE biotech Candid Therapeutics scores Nasdaq listing via reverse merger with rare disease-focused Rallybio | ||
| 02.03. | Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout | ||
| 02.03. | FDA fully releases clinical hold on Intellia CRISPR gene therapy trials | ||
| 02.03. | UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy | ||
| 02.03. | United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition | ||
| 02.03. | BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline | ||
| 02.03. | Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potential | ||
| 02.03. | Roche reports another phase 3 multiple sclerosis win but deaths add to safety questions |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.